{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:29:00Z","timestamp":1768454940946,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.02.017","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T08:40:57Z","timestamp":1582101657000},"page":"2816-2826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-5836","authenticated-orcid":false,"given":"Regnerus A.","family":"Vos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hella","family":"Pasmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Tymchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alcira V.A.","family":"Janga-Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharda","family":"Baboe-Kalpoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Hulshof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2020.02.017_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","article-title":"Clinician's guide to human papillomavirus immunology: knowns and unknowns","volume":"9","author":"Einstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.017_b0010","unstructured":"International Agency for Research on Cancer (IARC). Cancer Fact Sheets. Available from https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers."},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.017_b0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2020.02.017_b0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/07357900801975280","article-title":"Prevalence of cancer-associated viral infections in healthy afro-Caribbean populations: a review of the literature","volume":"26","author":"Ragin","year":"2008","journal-title":"Cancer Invest"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.02.017_b0025","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1750-9378-4-S1-S9","article-title":"Comparisons of high-risk cervical HPV infections in Caribbean and US populations","volume":"4","author":"Ragin","year":"2009","journal-title":"Infect Agent Cancer."},{"key":"10.1016\/j.vaccine.2020.02.017_b0030","unstructured":"van Lier EA, Oomen PJ, Giesbers H, van Vliet JA, Drijfhout IH, Zonnenberg-Hoff IF, et al. Vaccination Coverage and Annual Report National Immunisation Programme Netherlands 2018 [in Dutch: Vaccinatiegraad en Jaarverslag Rijksvaccinatieprogramma Nederland 2018]. Bilthoven: RIVM; 2019. Contract No.: RIVM-2019-0015."},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.017_b0035","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jmv.23616","article-title":"Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme","volume":"85","author":"Mollers","year":"2013","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.017_b0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12879-019-4019-y","article-title":"Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands","volume":"19","author":"Verberk","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2020.02.017_b0045","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1016\/j.vaccine.2012.08.068","article-title":"Seroprevalence of seven high-risk HPV types in The Netherlands","volume":"30","author":"Scherpenisse","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.017_b0050","doi-asserted-by":"crossref","first-page":"1631s","DOI":"10.1093\/jn\/131.5.1631S","article-title":"Use of filter paper for the collection and analysis of human whole blood specimens","volume":"131","author":"Mei","year":"2001","journal-title":"J Nutr"},{"key":"10.1016\/j.vaccine.2020.02.017_b0055","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard - Sixth Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2013. Contract No.: CLSI document NBS01-A6."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2020.02.017_b0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.02.017_b0065","series-title":"Mathematical statistics: basic ideas and selected topics","first-page":"101","article-title":"Basic heuristics of estimation","author":"Bickel","year":"2001"},{"key":"10.1016\/j.vaccine.2020.02.017_b0070","unstructured":"Statistics Netherlands (CBS). Population Caribbean Netherlands, 1 January 2017 [updated 23 January 2018; cited 7 June 2019]. Available from: https:\/\/www.cbs.nl\/en-gb\/custom\/2018\/04\/population-caribbean-netherlands-1-januari-2017."},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.017_b0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0950268816002132","article-title":"Distinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination","volume":"145","author":"Grunberg","year":"2017","journal-title":"Epidemiol Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.017_b0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/sextrans-2017-053109","article-title":"High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curacao: implications for choice of prophylactic HPV vaccine","volume":"94","author":"Hooi","year":"2018","journal-title":"Sex Transm Infect."},{"key":"10.1016\/j.vaccine.2020.02.017_b0085","unstructured":"The Netherlands Comprehensive Cancer Organisation (IKNL). Cancer Registry. 2019. Available from: https:\/\/www.iknl.nl\/."},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.017_b0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/IGC.0b013e31823c2469","article-title":"Age-specific seroprevalence of human papillomavirus 16, 18, 31, and 58 in women of a rural town of Colombia","volume":"22","author":"Bedoya","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.017_b0095","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.bjc.6601272","article-title":"Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica","volume":"89","author":"Wang","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2020.02.017_b0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2334-14-361","article-title":"Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile","volume":"14","author":"Castro","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.017_b0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990129)80:3<339::AID-IJC1>3.0.CO;2-F","article-title":"HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates","volume":"80","author":"Strickler","year":"1999","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.017_b0110","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/OLQ.0b013e31820bc880","article-title":"Prevalence of human papillomavirus antibodies in males and females in England","volume":"38","author":"Desai","year":"2011","journal-title":"Sex Transm Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.02.017_b0115","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1086\/587895","article-title":"Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia","volume":"46","author":"Newall","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.02.017_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000091","article-title":"Seroprevalence of 34 human papillomavirus types in the German general population","volume":"4","author":"Michael","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.02.017_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2019.03.022","article-title":"Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany - Results from a nationwide population-based survey","volume":"83","author":"Loenenbach","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.02.017_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048807","article-title":"Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995\u201396 and 2006\u201307 in The Netherlands","volume":"7","author":"Scherpenisse","year":"2012","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2020.02.017_b0135","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1086\/430274","article-title":"Seroprevalence of human papillomavirus type 16 in children","volume":"191","author":"Dunne","year":"2005","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.017_b0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jog.13248","article-title":"Possible non-sexual modes of transmission of human papilloma virus","volume":"43","author":"Sabeena","year":"2017","journal-title":"J Obstet Gynaecol Res."},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.017_b0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.017_b0150","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.017_b0155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nygard","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.017_b0160","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","article-title":"Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines","volume":"26","author":"Wheeler","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2020.02.017_b0165","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/344354","article-title":"Seroprevalence of human papillomavirus type 16 infection in the United States","volume":"186","author":"Stone","year":"2002","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.017_b0170","first-page":"292","article-title":"Evidence on delay in sexual initiation, multiple partnerships and condom use among young people: review of Caribbean HIV behavioural studies","volume":"62","author":"Allen","year":"2013","journal-title":"West Ind Med J"},{"key":"10.1016\/j.vaccine.2020.02.017_b0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pvr.2018.03.006","article-title":"Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16\u201364 years in Puerto Rico","volume":"5","author":"Ortiz","year":"2018","journal-title":"Papillomavirus Res (Amsterdam, Netherlands)"},{"issue":"11","key":"10.1016\/j.vaccine.2020.02.017_b0180","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/OLQ.0b013e3181e1a2c5","article-title":"Seroprevalence and correlates of human papillomavirus 16\/18 seropositivity among young women in Costa Rica","volume":"37","author":"Coseo","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.017_b0185","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/AOG.0b013e3181edbeba","article-title":"Prevalence and seroprevalence of high-risk human papillomavirus infection","volume":"116","author":"Kim","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.017_b0190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/OLQ.0000000000000409","article-title":"Determinants of high-risk human papillomavirus seroprevalence and DNA prevalence in mid-adult women","volume":"43","author":"Sadate-Ngatchou","year":"2016","journal-title":"Sex Transm Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2020.02.017_b0195","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/ijc.28215","article-title":"Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study","volume":"133","author":"Wilson","year":"2013","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.017_b0200","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1258\/0956462011923615","article-title":"Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients","volume":"12","author":"Slavinsky","year":"2001","journal-title":"Int J STD AIDS"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.017_b0205","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.017_b0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-015-0072-4","article-title":"Sample selection, recruitment and participation rates in health examination surveys in Europe-experience from seven national surveys","volume":"15","author":"Mindell","year":"2015","journal-title":"BMC Med Res Method"},{"issue":"6","key":"10.1016\/j.vaccine.2020.02.017_b0215","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.017_b0220","unstructured":"Health Council of the Netherlands. Vaccination against HPV [in Dutch: Vaccinatie tegen HPV]. The Hague: Health Council of the Netherlands; 2019. Report No.: 2019\/09."},{"issue":"9","key":"10.1016\/j.vaccine.2020.02.017_b0225","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1016\/S1470-2045(19)30512-1","article-title":"Cancer control in the Caribbean island countries and territories: some progress but the journey continues","volume":"20","author":"Spence","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:35Z","timestamp":1759401695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20302048"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}